Home / Recalls / Sciegen Pharmaceuticals Inc / D-0271-2019

D-0271-2019 Class II Terminated

Recalled by Sciegen Pharmaceuticals Inc — Hauppauge, NY

Recall Details

Product Type
Drugs
Report Date
November 28, 2018
Initiation Date
October 29, 2018
Termination Date
September 25, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
18,760 HDPE bottles

Product Description

GSMS Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 60429-641-30), (b) 90-count bottle (NDC 60429-641-90), Rx Only, Manufactured by ScieGen Pharmaceuticals, Inc. Hauppauge, NY 11788, Marketed by: GSMS Incorporated Camarillo, CA 93012 USA.

Reason for Recall

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Distribution Pattern

Nationwide

Code Information

60429-641-90 Irbesartan 150mg Tablets, 90 Count Bottle B161003 Sep-19 B161004 Sep-19 B161006 Sep-19 B161007 Sep-19 B161008 Nov-19 B161009 Nov-19 B161010 Nov-19 C161001 Feb-20 C161003 May-20 60429-641-30 Irbesartan 150mg Tablets, 30 Count Bottle GS019526 Nov-19 GS020252 Nov-19 GS020958 Nov-19

Other recalls by Sciegen Pharmaceuticals Inc

  • D-0354-2023 Class III — Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by (February 17, 2023)
  • D-0268-2019 Class II — Westminister Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 69367-120 (October 29, 2018)
  • D-0267-2019 Class II — Westminister Irbesartan Tablets, USP, 75 mg (a) 30-count bottle (NDC 69367-119-0 (October 29, 2018)
  • D-0270-2019 Class II — GSMS Irbesartan Tablets, USP, 75 mg, 30-count bottle, Rx Only, Manufactured by S (October 29, 2018)
  • D-0272-2019 Class II — GSMS Irbesartan Tablets, USP, 300 mg,(a) 30-count bottle (NDC 60429-642-30), (b) (October 29, 2018)
  • D-0269-2019 Class II — Westminister Irbesartan Tablets, USP, 300mg, Rx Only,(a) 30-count bottle (NDC 69 (October 29, 2018)